CAGRILINTIDE
Cagrilintide has been designed to provide prolonged activity compared with naturally occurring amylin. Clinical research has investigated how activation of amylin-related pathways may influence appetite, food intake, body weight, and metabolic regulation.
Researchers have studied cagrilintide both independently and in combination with GLP-1 receptor agonists, particularly semaglutide. This combination research, commonly referred to as CagriSema, is examining how complementary amylin and GLP-1 pathways may affect appetite regulation and body-weight management.
Unlike many compounds in early-stage peptide research, cagrilintide has progressed into human clinical trials. However, research remains ongoing, and its investigational findings should not be interpreted as establishing the research product offered here as an approved treatment or as providing therapeutic benefit.
For laboratory research purposes only. Not for human consumption
Kruse et al., 2021, Journal of Medicinal Chemistry: Covers the development of cagrilintide as a stable, long-acting amylin analogue and the research behind its selection for clinical development.
Lau et al., 2021, The Lancet: A randomized Phase 2 trial involving 706 participants assigned to cagrilintide groups. It directly investigated body-weight effects, safety, tolerability, and dose response in adults with overweight or obesity.
Enebo et al., 2021, The Lancet: Phase 1b research examining cagrilintide administered with semaglutide, including safety, tolerability, pharmacokinetics and pharmacodynamics.
Frias et al., 2023, The Lancet: Phase 2 research comparing cagrilintide plus semaglutide with the individual components in people with type 2 diabetes, including effects on body weight and glycemic measures.
